Telik Announces Publication of Positive Phase 1 Results of a Multicenter Study of Ezatiostat Hydrochloride (TELINTRA(R), TLK199) Tablets In Patients With Myelodysplastic Syndrome
PALO ALTO, Calif., Aug. 3 /PRNewswire-FirstCall/ -- Telik, Inc.
(NASDAQ: TELK) today announced that the positive
results from a Phase 1 multicenter, dose escalation study of
ezatiostat hydrochloride (TELINTRA, TLK199) tablets in patients
with Myelodysplastic Syndrome (MDS) have been published in a
leading peer reviewed journal, Blood, 25 June 2009; Vol. 113, No.
26, pp. 6533-6540. Positive results from a separate Phase 1-2a
study in MDS patients involving an intravenous formulation of
TELINTRA were published earlier in the Journal of Hematology and
Oncology,13 May 2009; Vol. 2, No.20, pp. 20-32. The findings
reported from these studies support the further development of
TELINTRA. Phase 2 studies are ongoing in MDS (enrollment completion
expected by year end), and Severe Chronic Idiopathic Neutropenia.
Reprints of both publications are available from Telik.
Background on MDS and TELINTRA
MDS is a heterogeneous group of blood stem cell disorders of
increasing incidence. MDS is characterized by ineffective blood
cell production involving one or more of the red cell, white cell
or platelet lineages and with MDS patients having a variable risk
of progression to leukemia. There remains a need for effective,
well tolerated therapies for MDS having novel mechanisms of action.
TELINTRA has a novel mechanism of action that inhibits a target
enzyme called glutathione S- transferase P1-1 which in turn
facilitates the activation of JNK kinase, a key regulator of
cellular growth and differentiation of blood. TELINTRA has been
shown to stimulate normal multilineage differentiation of blood
stem cell precursors and induce cancer cell death in human leukemia
Telik, Inc. of Palo Alto, CA, is a clinical stage drug
development company focused on discovering and developing small
molecule drugs to treat cancer and inflammatory diseases. The
company's most advanced investigational drug candidates in clinical
development are TELINTRA, a modified glutathione analog for the
treatment of cytopenias due to myelodysplastic syndrome or
chemotherapy, and TELCYTA , a tumor-activated prodrug for the
treatment of advanced ovarian cancer and non-small cell lung
cancer. Telik's product candidates were discovered using its
proprietary drug discovery technology, TRAP , which enables the
rapid and efficient discovery of small molecule drug
TELIK, the Telik logo, TELINTRA, TELCYTA and TRAP are trademarks
or registered trademarks of Telik, Inc.
Source: Telik, Inc.
CONTACT: Patricia P. Frias, Corporate Communications of Telik,
Posted: August 2009